Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Statens Serum Institut currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single action represents the full extent of the company's active prosecution at the USPTO. The focus on biotechnology indicates that the company is currently seeking protection for complex biological or medicinal inventions within a specialized regulatory framework.
The prosecution involves 1 distinct examiner and 1 distinct art unit. This one-to-one relationship between the pending action, the examiner, and the art unit indicates a very focused prosecution environment. For the applicant, this means there is only one set of examiner preferences and one art unit's specific guidelines to navigate, which reduces the complexity of the legal strategy.
Browe, David is the busiest examiner for the portfolio, with 1 pending office action. As this examiner is responsible for the only pending action, they handle all current matters for the company. Practitioners should focus their strategy on the specific historical patterns and requirements of this individual examiner to effectively manage the company's pending biotechnology interests.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| §112 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BROWE, DAVID | 1 | 26.4% | +27.3% |
| SABOUR, GHAZAL | 1 | 37.8% | +43.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17207541 | Methods for Evaluation of Gestational Progress and Preterm Abortion for Clinical Intervention and Applications Thereof | SABOUR, GHAZAL | 9d |
| 17996379 | LIPOSOMAL COMPOSITION FOR PREVENTING OR EARLY TREATMENT OF PATHOGENIC INFECTION | BROWE, DAVID | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17207541 | Methods for Evaluation of Gestational Progress and Preterm Abortion for Clinical Intervention and Applications Thereof | SABOUR, GHAZAL | 9d |
| 17996379 | LIPOSOMAL COMPOSITION FOR PREVENTING OR EARLY TREATMENT OF PATHOGENIC INFECTION | BROWE, DAVID | — |
| Art Unit | Apps |
|---|---|
| 1617 | 1 |
| 1686 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17996379 | LIPOSOMAL COMPOSITION FOR PREVENTING OR EARLY TREATMENT OF PATHOGENIC INFECTION | BROWE, DAVID | 1617 | §112 | Non-Final OA | — | Pending | Oct 17, 2022 |
| 17207541 | Methods for Evaluation of Gestational Progress and Preterm Abortion for Clinical Intervention and Applications Thereof | SABOUR, GHAZAL | 1686 | §101§103§112 | Non-Final OA | 9d | Pending | Mar 19, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial